575 related articles for article (PubMed ID: 18945962)
21. The effect of killer cell immunoglobulin-like receptor genotype on outcome of hematopoietic stem cell transplantation from matched sibling.
Elfishawi SM; Mossallam GI; El-Fattah RA; El-Haddad A; Kamel AM
Hum Immunol; 2017 Nov; 78(11-12):684-691. PubMed ID: 28993188
[TBL] [Abstract][Full Text] [Related]
22. Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation.
McQueen KL; Dorighi KM; Guethlein LA; Wong R; Sanjanwala B; Parham P
Hum Immunol; 2007 May; 68(5):309-23. PubMed ID: 17462498
[TBL] [Abstract][Full Text] [Related]
23. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.
Venstrom JM; Pittari G; Gooley TA; Chewning JH; Spellman S; Haagenson M; Gallagher MM; Malkki M; Petersdorf E; Dupont B; Hsu KC
N Engl J Med; 2012 Aug; 367(9):805-16. PubMed ID: 22931314
[TBL] [Abstract][Full Text] [Related]
24. Role of killer immunoglobulin-like receptor-ligand interactions in human leukocyte antigen-matched sibling hematopoietic stem cell transplantation.
Kanga U; Mourya M; Seth T; George J; Sood P; Sharma R; Saxena A; Mehra NK
Transplant Proc; 2012 May; 44(4):919-21. PubMed ID: 22564585
[TBL] [Abstract][Full Text] [Related]
25. KIR2DS4 and Its Variant KIR1D Are Associated with Acute Graft-versus-Host Disease, Cytomegalovirus, and Overall Survival after Sibling-Related HLA-Matched Transplantation in Patients with Donors with KIR Gene Haplotype A.
Wu X; Yao Y; Bao X; Zhou H; Tang X; Han Y; Ma X; Liu Y; Chen J; Zhou H; Jing S; Gu B; Xu Y; Sun A; He J; Wu D
Biol Blood Marrow Transplant; 2016 Feb; 22(2):220-225. PubMed ID: 26476204
[TBL] [Abstract][Full Text] [Related]
26. Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation.
Sobecks RM; Wang T; Askar M; Gallagher MM; Haagenson M; Spellman S; Fernandez-Vina M; Malmberg KJ; Müller C; Battiwalla M; Gajewski J; Verneris MR; Ringdén O; Marino S; Davies S; Dehn J; Bornhäuser M; Inamoto Y; Woolfrey A; Shaw P; Pollack M; Weisdorf D; Milller J; Hurley C; Lee SJ; Hsu K
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1589-96. PubMed ID: 25960307
[TBL] [Abstract][Full Text] [Related]
27. [Influence of donor activating or inhibitory KIR on prognosis of unmanipulated allogeneic hematopoietic stem cell transplantation].
Liang ZY; Ren HY; Cen XN; Qiu ZX; Wang LH; Ou JP; Li Y; Wang MJ; Wang WS; Xu WL; Dong YJ; Yin Y; Sun YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):155-60. PubMed ID: 23484711
[TBL] [Abstract][Full Text] [Related]
28. Increased donor inhibitory KIR with known HLA interactions provide protection from relapse following HLA matched unrelated donor HCT for AML.
Krieger E; Qayyum R; Keating A; Toor A
Bone Marrow Transplant; 2021 Nov; 56(11):2714-2722. PubMed ID: 34234295
[TBL] [Abstract][Full Text] [Related]
29. Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation.
Rangarajan HG; Pereira MSF; Brazauskas R; St Martin A; Kussman A; Elmas E; Verneris MR; Gadalla SM; Marsh SGE; Paczesny S; Spellman SR; Lee SJ; Lee DA
Transplant Cell Ther; 2021 Nov; 27(11):926.e1-926.e10. PubMed ID: 34407489
[TBL] [Abstract][Full Text] [Related]
30. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry.
Farag SS; Bacigalupo A; Eapen M; Hurley C; Dupont B; Caligiuri MA; Boudreau C; Nelson G; Oudshoorn M; van Rood J; Velardi A; Maiers M; Setterholm M; Confer D; Posch PE; Anasetti C; Kamani N; Miller JS; Weisdorf D; Davies SM;
Biol Blood Marrow Transplant; 2006 Aug; 12(8):876-84. PubMed ID: 16864058
[TBL] [Abstract][Full Text] [Related]
31. [The role of different KIR haplotypes in haplo-identical hematopoietic stem cell transplantation].
Bao X; He J; Wang M; Yuan X; Li Y; Zhang T; Li L; Chen L; Wu D
Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):20-5. PubMed ID: 26876248
[TBL] [Abstract][Full Text] [Related]
32. Donor KIR Genotype Impacts on Clinical Outcome after T Cell-Depleted HLA Matched Related Allogeneic Transplantation for High-Risk Pediatric Leukemia Patients.
Escudero A; Martínez-Romera I; Fernández L; Valentín J; González-Vicent M; Vicario JL; Madero-Jarabo R; Diaz MÁ; Pérez-Martínez A
Biol Blood Marrow Transplant; 2018 Dec; 24(12):2493-2500. PubMed ID: 30145228
[TBL] [Abstract][Full Text] [Related]
33. How important is NK alloreactivity and KIR in allogeneic transplantation?
Shaffer BC; Hsu KC
Best Pract Res Clin Haematol; 2016 Dec; 29(4):351-358. PubMed ID: 27890259
[TBL] [Abstract][Full Text] [Related]
34. The impact of recipient HLA-Cw and donor killer immunoglobulin-like receptor genotyping on the outcome of patients receiving HLA-matched sibling donor hematopoietic stem cell transplantation for myeloid malignancies.
Wang H; He Y; Zhai WJ; Wang M; Zhou Z; Zhao YX; Feng SZ; Han MZ
Swiss Med Wkly; 2013; 143():w13717. PubMed ID: 23299929
[TBL] [Abstract][Full Text] [Related]
35. The beneficial impact of missing KIR ligands and absence of donor KIR2DS3 gene on outcome following unrelated hematopoietic SCT for myeloid leukemia in the Chinese population.
Wu GQ; Zhao YM; Lai XY; Luo Y; Tan YM; Shi JM; Li L; Zheng WY; Zhang J; Hu XR; Jin AY; He JS; Xie WZ; Ye XJ; Cai Z; Lin MF; Huang H
Bone Marrow Transplant; 2010 Oct; 45(10):1514-21. PubMed ID: 20173784
[TBL] [Abstract][Full Text] [Related]
36. Clinical impact of KIR haplotypes in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic hematopoietic stem cell transplantation.
Moyer AM; Hashmi SK; Kroning CM; Patnaik M; Litzow M; Gastineau DA; Hogan WJ; Jacob EK; Kreuter JD; Wakefield LL; Gandhi MJ
Leuk Lymphoma; 2023 Mar; 64(3):671-678. PubMed ID: 36448323
[TBL] [Abstract][Full Text] [Related]
37. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation.
Kröger N; Binder T; Zabelina T; Wolschke C; Schieder H; Renges H; Ayuk F; Dahlke J; Eiermann T; Zander A
Transplantation; 2006 Oct; 82(8):1024-30. PubMed ID: 17060849
[TBL] [Abstract][Full Text] [Related]
38. KIR Donor Selection: Feasibility in Identifying better Donors.
Weisdorf D; Cooley S; Wang T; Trachtenberg E; Haagenson MD; Vierra-Green C; Spellman S; Spahn A; Vogel J; Kobusingye H; Fehninger T; Woolfrey A; Devine S; Ross M; Waller EK; Sobecks R; Parham P; Guethlein LA; Marsh SGE; Miller J;
Biol Blood Marrow Transplant; 2019 Jan; 25(1):e28-e32. PubMed ID: 30149149
[TBL] [Abstract][Full Text] [Related]
39. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy.
Hsu KC; Gooley T; Malkki M; Pinto-Agnello C; Dupont B; Bignon JD; Bornhäuser M; Christiansen F; Gratwohl A; Morishima Y; Oudshoorn M; Ringden O; van Rood JJ; Petersdorf E;
Biol Blood Marrow Transplant; 2006 Aug; 12(8):828-36. PubMed ID: 16864053
[TBL] [Abstract][Full Text] [Related]
40. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.
Ringdén O; Pavletic SZ; Anasetti C; Barrett AJ; Wang T; Wang D; Antin JH; Di Bartolomeo P; Bolwell BJ; Bredeson C; Cairo MS; Gale RP; Gupta V; Hahn T; Hale GA; Halter J; Jagasia M; Litzow MR; Locatelli F; Marks DI; McCarthy PL; Cowan MJ; Petersdorf EW; Russell JA; Schiller GJ; Schouten H; Spellman S; Verdonck LF; Wingard JR; Horowitz MM; Arora M
Blood; 2009 Mar; 113(13):3110-8. PubMed ID: 19059878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
